A study published in the Canadian Medical Association Journal revealed that a third booster dosage of the Covid-19 vaccination was linked to a 90% decrease in mortality in individuals with numerous medical conditions instead of just two doses.

The study compared data from adults (18 years or older) who received a third dose between November 2021 and March 2022 and had two or more chronic diseases, such as high blood pressure, diabetes, or chronic kidney disease, to those who had only received two doses. The study included 127,318 CoronaVac recipients (94,977 who received a booster) and 120,724 Pfizer-BioNTech vaccine recipients (of whom 87 289 received a booster). 

The findings showed that persons with multimorbidity who got a homologous booster dose of BNT162b2, an mRNA vaccine, or CoronaVac, an inactivated whole-virus vaccination, had a significantly lower risk of COVID-19-related death. According to researchers, these findings confirm that booster doses of vaccines from two separate technological platforms can reduce mortality among people with multimorbidity during the Omicron pandemic.

The results imply that this timely, extensive public health initiative has played a critical role in reducing the mortality rate during the outbreak, particularly among those with several chronic conditions.

Experts concluded that the study would add to the shreds of evidence stating that booster doses offer significant protection against mortality due to COVID-19.

(Source: https://www.tribuneindia.com/news/coronavirus/third-covid-booster-linked-with-90-per-cent-reduction-in-deaths-study-475022)